A Study of TCR-Redirected T Cell Infusion to Prevent Hepatocellular Carcinoma Recurrence Post Liver Transplantation

Inclusion Criteria: * Diagnosis as hepatocellular carcinoma (HCC) * Underwent liver transplantation * Seropositive for hepatitis B surface antigen (HBsAg), or presence of HBV DNA or HBV RNA before liver transplantation * Expression of TCR-T target epitopes within specific human leukocyte antigen (HLA) class I profile * No major post-operative complication * Life expectancy of at least 3 months * Ability to provide informed consent * Ability to comply with study procedures Exclusion Criteria: * Known, clinically suspected or has history or central nervous system (CNS) and bone metastasis * Significant ongoing immunologic rejection based on pathology and clinical diagnosis * Evidence or history of significant bleeding diathesis or coagulopathy * Prior exposure to any cell therapy such as, but not limited to NK, CIK, DC, CTL, stem cells therapy * Known history of testing positive for human immunodeficiency virus (HIV) 1 or 2 or known acquired immunodeficiency syndrome (AIDS) * Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection * Women who are pregnant or breast-feeding * Any condition that is unstable or which could jeopardise the safety of the patient and his/her compliance in the study